Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Clinical Report. 2014 Authors' conclusions Based on the findings of two systematic reviews, it appears that somatropin treatment results in greater and more rapid gains in height, including final height, compared with no treatment. However, whether QoL is improved in those treated with somatropin compared with those not treated is uncertain. Genotropin is one of several somatropin products approved by Health Canada for the treatment of short stature associated with TS; others include Humatrope, Nutropin, and Saizen. There is insufficient evidence on the comparative efficacy and safety of the somatropin products for the treatment of short stature associated with TS. In clinical practice, product selection is generally based upon patient and/or parent preference in consultation with the clinician. Indexing Status Subject indexing assigned by CRD MeSH Human Growth Hormones; Turner Syndrome Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000803 Date abstract record published 17/07/2014 |